Chinese Investor Consortium Buys SciClone But Relisting Possible
Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.
You may also be interested in...
Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.